Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma

Powles, T, Lackner, MR, Oudard, S et al. (18 more authors) (2016) Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 34 (14). pp. 1660-1668. ISSN 0732-183X

Abstract

Metadata

Authors/Creators:
  • Powles, T
  • Lackner, MR
  • Oudard, S
  • Escudier, B
  • Ralph, C ORCID logo https://orcid.org/0000-0001-5581-2987
  • Brown, JE
  • Hawkins, RE
  • Castellano, D
  • Rini, BI
  • Staehler, MD
  • Ravaud, A
  • Lin, W
  • O’Keeffe, B
  • Wang, Y
  • Lu, S
  • Spoerke, JM
  • Huw, L-Y
  • Byrtek, M
  • Zhu, R
  • Ware, JA
  • Motzer, RJ
Copyright, Publisher and Additional Information: © 2016 by American Society of Clinical Oncology.Reproduced in accordance with the publisher's self-archiving policy.
Dates:
  • Published (online): 7 March 2016
  • Published: 10 May 2016
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 05 Dec 2018 14:52
Last Modified: 05 Dec 2018 14:52
Status: Published
Publisher: American Society of Clinical Oncology
Identification Number: https://doi.org/10.1200/JCO.2015.64.8808

Share / Export

Statistics